{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7"}]}],"title":"In-response at Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7"}]}],"title":"In-response at Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.3"}]}],"title":"Not in-response at Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.3"}]}],"title":"Not In-response at Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"}],"units":"Participants"}],"description":"The response status at 6 and 12 months after start of trial treatment according to RECIST 1.1 (as determined by the IERC) was determined. A participant was considered to be in response at the given timepoint (6 or 12 months after the start of the participant's treatment) if the participant had a documented response (PR or CR) prior to that timepoint, and neither died nor experienced disease progression according to the RECIST 1.1 nor was lost to follow-up up to the given timepoint. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (SLD) of all lesions. Percentage of participants in response and not in response according to RECIST1.1 at 6 and 12 months were reported.","groups":[{"description":"Participants with metastatic Merkel cell carcinoma (MCC) after failing first-line chemotherapy received Avelumab at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.","id":"OG000","title":"Part A: Avelumab"}],"paramType":"NUMBER","populationDescription":"Intent-to-Treat analysis set included all participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"At Month 6 and 12","title":"Part A: Participant's Response Status According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 at 6 and 12 Months","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}